The coxsackievirus and adenovirus receptor (CAR) mediates viral attachment and infection, but its physiologic functions have not been described. In nonpolarized cells, CAR localized to homotypic intercellular contacts, mediated homotypic cell aggregation, and recruited the tight junction protein ZO-1 to sites of cell-cell contact. In polarized epithelial cells, CAR and ZO-1 colocalized to tight junctions and could be coprecipitated from cell lysates. CAR expression led to reduced passage of macromolecules and ions across cell monolayers, and soluble CAR inhibited the formation of functional tight junctions. Virus entry into polarized epithelium required disruption of tight junctions. These results indicate that CAR is a component of the tight junction and of the functional barrier to paracellular solute movement. Sequestration of CAR in tight junctions may limit virus infection across epithelial surfaces.G roup B coxsackieviruses and a number of adenovirus serotypes initiate infection by binding to the coxsackievirus and adenovirus receptor (CAR) (1-3). CAR is a 46-kDa integral membrane protein with a typical transmembrane region, a long cytoplasmic domain, and an extracellular region composed of two Ig-like domains (1, 2). Both adenovirus (4) and coxsackievirus (5) interact with the N-terminal domain. Homologs of human CAR have been characterized in mice (2, 6), rats, pigs, dogs (7), and zebrafish (8). The murine and human proteins are very similar (91% amino acid identity within the extracellular domain, 77% within the transmembrane domain, and 95% identity within the cytoplasmic domain). Variant isoforms of CAR, which differ only at the C terminus and which most likely result from alternative splicing, have been identified in mice (6), humans, and rats (7). Despite evidence of its evolutionary conservation in mammals and nonmammalian vertebrates, the function of CAR is not known.Tight junctions are continuous circumferential intercellular contacts at the apical poles of lateral cell membranes, appearing in electron micrographs as a series of discrete contacts between the plasma membranes of adjacent cells (9). Tight junctions form a barrier that regulates the paracellular transit of water, solutes, and immune cells across an epithelium (10), and are essential for establishing cell polarity by separating the apical and basolateral domains of polarized epithelial cells (11). ZO-1, the first tight junction protein identified (12, 13), is an intracellular peripheral membrane scaffolding protein important for tight junction structure and assembly. In the present study, we found that in polarized epithelial cells CAR is expressed at the tight junction, where it associates with ZO-1 and functions in the barrier to the movement of macromolecules and ions. Materials and MethodsCell Culture. T-84, CALU-3, and 16HBE14o-cells were grown in 10% CO 2 in a 1:1 mixture of DMEM and Ham's F-12 medium with 10% FCS. To establish polarized monolayers, 5 ϫ 10 5 cells per well were plated on 12-mm diameter polyester filters with a ...

A single nucleotide polymorphism in the DAB2IP gene is associated with risk of aggressive prostate cancer (PCa), and loss of DAB2IP expression is frequently detected in metastatic PCa. However, the functional role of DAB2IP in PCa remains unknown. Here, we show that the loss of DAB2IP expression initiates epithelial-to-mesenchymal transition (EMT), which is visualized by repression of E-cadherin and up-regulation of vimentin in both human normal prostate epithelial and prostate carcinoma cells as well as in clinical prostate-cancer specimens. Conversely, restoring DAB2IP in metastatic PCa cells reversed EMT. In DAB2IP knockout mice, prostate epithelial cells exhibited elevated mesenchymal markers, which is characteristic of EMT. Using a human prostate xenograft-mouse model, we observed that knocking down endogenous DAB2IP in human carcinoma cells led to the development of multiple lymph node and distant organ metastases. Moreover, we showed that DAB2IP functions as a scaffold protein in regulating EMT by modulating nuclear β-catenin/Tcell factor activity. These results show the mechanism of DAB2IP in EMT and suggest that assessment of DAB2IP may provide a prognostic biomarker and potential therapeutic target for PCa metastasis. P rostate cancer (PCa) has surpassed lung cancer as the leading cancer among American men (1). In the absence of metastasis, prostate cancer is largely a treatable disease. Thus, early diagnosis of patients who will develop PCa metastasis could reduce the mortality and morbidity associated with this disease. The development of metastasis depends on the migration and invasion of cancer cells from the primary tumor into the surrounding tissue. To acquire such invasive abilities, carcinoma cells may acquire unique phenotypic changes such as epithelial-tomesenchymal transition (EMT). EMT is a highly conserved cellular process that allows polarized, generally immotile epithelial cells to convert to motile mesenchymal-appearing cells. This process was initially recognized during several critical stages of embryonic development and has more recently been implicated in promoting carcinoma invasion and metastasis (2-4). During EMT, three major changes occur: (i) morphological changes from a cobblestone-like monolayer of epithelial cells to dispersed, spindle-shaped mesenchymal cells with migratory protrusions; (ii) changes of differentiation markers from cell-cell junction proteins and cytokeratin intermediate filaments to vimentin filaments and fibronectin; and (iii) acquisition of invasiveness through the extracellular matrix (4). Decreased E-cadherin expression or gain of vimentin expression is closely correlated with various indices of PCa progression, including grade, local invasiveness, dissemination into the blood, and tumor relapse after radiotherapy (5-8).A recent study using genome-wide association data reveals that a single nucleotide polymorphism probe located in the first intron of DAB2IP gene associates with the risk of aggressive PCa (9). The functional role of DAB2IP in PCa is poor...

In metastatic prostate cancer (PCa) cells, imbalance between cell survival and death signals such as constitutive activation of phosphatidylinositol 3-kinase (PI3K)-Akt and inactivation of apoptosisstimulated kinase (ASK1)-JNK pathways is often detected. Here, we show that DAB2IP protein, often down-regulated in PCa, is a potent growth inhibitor by inducing G 0/G1 cell cycle arrest and is proapoptotic in response to stress. Gain of function study showed that DAB2IP can suppress the PI3K-Akt pathway and enhance ASK1 activation leading to cell apoptosis, whereas loss of DAB2IP expression resulted in PI3K-Akt activation and ASK1-JNK inactivation leading to accelerated PCa growth in vivo. Moreover, glandular epithelia from DAB2IP ؊/؊ animal exhibited hyperplasia and apoptotic defect. Structural functional analyses of DAB2IP protein indicate that both proline-rich (PR) and PERIOD-like (PER) domains, in addition to the critical role of C2 domain in ASK1 activity, are important for modulating PI3K-Akt activity. Thus, DAB2IP is a scaffold protein capable of bridging both survival and death signal molecules, which implies its role in maintaining cell homeostasis.cell apoptosis ͉ prostate cancer ͉ signal transduction

Exosomes participate in cancer progression and metastasis by transferring bioactive molecules between cancer and various cells in the local and distant microenvironments. Such intercellular cross‐talk results in changes in multiple cellular and biological functions in recipient cells. Several hallmarks of cancer have reportedly been impacted by this exosome‐mediated cell‐to‐cell communication, including modulating immune responses, reprogramming stromal cells, remodeling the architecture of the extracellular matrix, or even endowing cancer cells with characteristics of drug resistance. Selectively, loading specific oncogenic molecules into exosomes highlights exosomes as potential diagnostic biomarkers as well as therapeutic targets. In addition, exosome‐based drug delivery strategies in preclinical and clinical trials have been shown to dramatically decrease cancer development. In the present review, we summarize the significant aspects of exosomes in cancer development that can provide novel strategies for potential clinical applications.